Colorectal Cancer Clinical Trial
Official title:
Walk on: A Community-based Approach to Promote Participation in Physical Activity Among Men Treated for Colorectal Cancer
Verified date | September 2018 |
Source | University of Ottawa |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In Canada, over 102,900 men are diagnosed with cancer each year. Of these, 81,000 are
diagnosed with colorectal cancer and an estimated 65% are expected to survive the disease for
at least 5 years. Men who have completed treatment for colorectal cancer face many adverse
physical, cognitive, psychological, and social effects. The Wellness Beyond Cancer Program at
The Ottawa Hospital is a cancer survivorship program that helps people who have completed
treatment for cancer, including men diagnosed with colorectal cancer, manage these effects.
The Wellness Beyond Cancer Program does this through education and referral to supportive
care services and programs offered throughout the city of Ottawa.
Group-based physical activity programs are one of the varied services and programs available
to adults diagnosed with cancer in Ottawa. Such programs are offered through the Ottawa
Regional Cancer Foundation (http://www.ottawacancer.ca) and Breast Cancer Action Ottawa
(http://bcaott.ca). Research on these programs show that group-based physical activity can
improve disease and treatment-related effects while promoting overall quality of life amongst
women with cancer. However, few of these programs have targeted men, even though their needs
and preferences have been shown to be very different from women. While men diagnosed with
colorectal cancer might also benefit from group-based physical activity programs offered in
the community, it is not known if such programs would effectively reach them and what the
impact would be on their quality of life after cancer treatment.
It is believed that a men's group-based walking program could be an effective way to reach
men and promote quality of life after cancer treatment. Therefore, a sustainable 8-week
group-based walking program was developed. This project will seek to explore the feasibility
and potential benefits of the program among men who have completed treatment for colorectal
cancer and who are referred to the program from staff at the Wellness Beyond Cancer Program
in a prospective single-arm trial.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 30, 2018 |
Est. primary completion date | September 30, 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Men 18 years of age or older; 2. Have completed treatment for colorectal cancer <1 year; 3. Willing to provide informed consent to participate in this study and willing to follow the study protocol; 4. Have the ability to walk without the use of an assistive device (including a cane) or the help of another person; 5. Able to read and understand English; 6. Medically cleared to participate in the walking program as determined by their referring Wellness Beyond Cancer Program healthcare provider. Exclusion Criteria: 1. Congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, uncontrolled angina, uncontrolled arrhythmia, myocardial infarction, major heart surgery, stroke, or pulmonary embolus; 2. Uncontrolled hypertension (systolic blood pressure>200 mm Hg and/or diastolic blood pressure >110 mm Hg); 3. The use of supplemental oxygen; 4. Severe arthritis (i.e., osteoarthritis or rheumatoid arthritis); 5. History of chest pain or severe shortness of breath either at rest or when engaging in physical activity; 6. Hip fracture, hip or knee replacement in the past 6 months; 7. Currently enrolled in another study involving a physical activity intervention. |
Country | Name | City | State |
---|---|---|---|
Canada | University of Ottawa | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
University of Ottawa |
Canada,
Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. — View Citation
Eaton WW, Muntaner C, Smith C, Tien A, Ybarra M. Center for Epidemiologic Studies Depression Scale: Review and revision (CESD and CESD-R), in The Use of Psychological Testing for Treatment Planning and Outcomes Assessment, M.E. Maruish, Editor. 2004, Lawrence Erlbaum: Mahwah, NJ. p. 363-377.
Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985 Sep;10(3):141-6. — View Citation
Marsh HW, Martin AJ, Jackson S. Introducing a short version of the physical self description questionnaire: new strategies, short-form evaluative criteria, and applications of factor analyses. J Sport Exerc Psychol. 2010 Aug;32(4):438-82. Erratum in: J Sport Exerc Psychol. 2010 Dec;32(6):909-11. — View Citation
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement, 1977. 1: p. 385-401.
Wagner L, Lai J-S, Cella D, Sweet J, Forrestal S. Chemotherapy-related cognitive deficits: development of the FACT-Cog instrument. Ann Behav Med, 2004. 27: p. S10.
Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res. 1999 May;8(3):181-95. — View Citation
Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. — View Citation
Wilson PM, Bengoechea EG. The relatedness to others in physical activity scale: evidence for structural and criterion validity. Journal of Applied Biobehavioral Research, 2010. 15(2): p. 61-87.
Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997 Feb;13(2):63-74. — View Citation
Yost KJ, Cella D, Chawla A, Holmgren E, Eton DT, Ayanian JZ, West DW. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J Clin Epidemiol. 2005 Dec;58(12):1241-51. Epub 2005 Oct 13. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment rates | The number of men who enrol in the study out of the number who are referred. | Through study completion, an average of 8 weeks | |
Primary | Retention rates | The number of men who complete the intervention and all scheduled assessments. | Through study completion, an average of 8 weeks | |
Primary | Adherence rates | The number of walking sessions men engage in out of the total recommended as part of the intervention. | Through study completion, an average of 8 weeks | |
Secondary | Change in Physical Activity Behaviour: Leisure Time Exercise Questionnaire (Godin & Shephard, 1985) | Change in participants' self-reported physical activity (over the past 7 days) from baseline to post-intervention. | Baseline (week 0) and post-intervention (week 8) | |
Secondary | Change in Quality of Life: Functional Assessment of Cancer Therapy (FACT)-Colorectal (Ward et al., 1999; Yost et al. 2005) | Change in participants' self-reported quality of life from baseline to post-intervention. | Baseline (week 0) and post-intervention (week 8) | |
Secondary | Change in Cognitive Functioning: FACT-Cognitive Function (Wagner et al., 2004) | Change in participants' self-reported cognitive functioning from baseline to post-intervention. | Baseline (week 0) and post-intervention (week 8) | |
Secondary | Change in Affect: Positive and Negative Affect Schedule (Watson et al., 1988) | Change in participants' self-reported affect from baseline to post-intervention. | Baseline (week 0) and post-intervention (week 8) | |
Secondary | Change in Depression: Center for Epidemiologic Studies Depression Scale 10-item Revised (Eaton et al., 2004; Radloff, 1977) | Change in participants' self-reported depressive symptoms from baseline to post-intervention. | Baseline (week 0) and post-intervention (week 8) | |
Secondary | Change in Social Support: Relatedness to Others in Physical Activity Scale (Wilson & Bengoechea, 2010) | Change in participants' self-reported perceptions of social support from baseline to post-intervention. | Baseline (week 0) and post-intervention (week 8) | |
Secondary | Change in Physical Self-Perceptions: Physical Self Description Questionnaire Short-Form (Marsh et al., 2010) | Change in participants' self-reported physical competence, confidence, and self-esteem from baseline to post-intervention. | Baseline (week 0) and post-intervention (week 8) | |
Secondary | Change in Stress: Perceived Stress Scale (Cohen et al., 1982) | Change in participants' self-reported perceptions of stress from baseline to post-intervention. | Baseline (week 0) and post-intervention (week 8) | |
Secondary | Change in Fatigue: Functional Assessment of Chronic Illness Therapy-Fatigue Scale (Yellen et al., 1997) | Change in participants' self-reported perceptions of fatigue from baseline to post-intervention. | Baseline (week 0) and post-intervention (week 8) | |
Secondary | Participants' Overall Experiences: Qualitative Interviews | Participants' perspectives on how the intervention contributed to their behavioural, physical, psychological and social functioning, as well as their overall quality of life. | Post-intervention (week 8) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |